Malang, East Java, Indonesia, Nov 25, 2020 - (ACN Newswire) - Brawijaya University (UB) in Malang, East Java has
developed an initial screening kit for diabetes. The Bioscience Rapid Test GAD65, developed by aresearch team led by
Prof. Dr. Aulanni'am, drh, DES, is ready for commercialization and use in early screening for Type I Diabetes Mellitus,
before measures and treatment are determined.
The reverse-flow immunochromatography-based detection kit identifies the presence of autoantibodies against GAD65, which
indicate damage to beta-pancreatic cells, a marker for Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults
(LADA).
Diabetes is a global health threat which can lead to complications that impact the quality of human life as well as
substantially add to health costs for families and countries. Its increasing prevalence has raised concerns globally and
prompted prevention efforts. Detecting and managing the condition through appropriate therapy is crucial for preventing
deterioration in the condition of people suffering from the metabolic disease.
The Bioscience Rapid Test GAD65 is among the downstream products developed as part of the cooperation between Brawijaya
University and state-owned pharmaceutical company PT Bio Farma (Persero). The preparation and production of the kit has
involved various levels of research and testing, based on the consensus and regulations set by the World Health
Organization (WHO) and the Indonesian Health Ministry.
The screening kit, which has a medical device distribution permit and meets the certification requirements for good
medical device manufacturing from the Indonesian Ministry of Health, is ready to be produced and widely distributed and
has been introduced to potential consumers in Spain, Taiwan, Japan, Saudi Arabia, Jordan, Madagascar, the Philippines,
and Malaysia.
As part of the collaboration for the downstreaming process of the kit, Brawijaya University has been designated as the
producer and PT Bio Farma as the main distributor of the patented product (ID. 0.022.556 B, 2009-Granted and
P00201910578, 2019-Registered).